USP22 regulates APL differentiation via PML-RARα stabilization and IFN repression

Autor: Lisa Kowald, Jens Roedig, Rebekka Karlowitz, Kristina Wagner, Sonja Smith, Thomas Juretschke, Petra Beli, Stefan Müller, Sjoerd J. L. van Wijk

Publikováno v: Cell Death Discovery, Vol 10, Iss 1, Pp 1-11 (2024)

Abstract Ubiquitin-specific peptidase 22 (USP22) is a deubiquitinating enzyme (DUB) that underlies tumorigenicity, proliferation, cell death and differentiation through deubiquitination of histone and non-histone targets. Ubiquitination determines st

Externí odkaz: https://doaj.org/article/0fc6c043461f4dadbb7ba5930e2dcbc7

USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING

Autor: Rebekka Karlowitz, Megan L. Stanifer, Jens Roedig, Geoffroy Andrieux, Denisa Bojkova, Marco Bechtel, Sonja Smith, Lisa Kowald, Ralf Schubert, Melanie Boerries, Jindrich Cinatl, Steeve Boulant, Sjoerd J. L. van Wijk

Publikováno v: Cell Death and Disease, Vol 13, Iss 8, Pp 1-14 (2022)

Abstract Pattern recognition receptors (PRRs) and interferons (IFNs) serve as essential antiviral defense against SARS-CoV-2, the causative agent of the COVID-19 pandemic. Type III IFNs (IFN-λ) exhibit cell-type specific and long-lasting functions i

Externí odkaz: https://doaj.org/article/e0cff6daeb78475a8d5002c6e431347e

Our Car As Power Plant

Autor: L. Verhoef, A. J. M. van Wijk

Fuel cell cars can provide more efficient and cleaner transportation. However, we use our cars for transportation only 5% of the time. When parked, the fuel cell in the car can produce electricity from hydrogen, which is cleaner and more efficient th

Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells

Autor: Christopher Wolf, Sonja Smith, Sjoerd J. L. van Wijk

Publikováno v: International Journal of Molecular Sciences, Vol 23, Iss 7, p 3567 (2022)

Mutations in the Von Hippel–Lindau (VHL) gene are the driving force in many forms of clear cell renal cell carcinoma (ccRCC) and promote hypoxia-inducible factor (HIF)-dependent tumor proliferation, metastasis and angiogenesis. Despite the progress

Externí odkaz: https://doaj.org/article/456b32f49aff42869d4dcbb0d985b70c

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγon T cells

Autor: Mary J van Helden, Seline A Zwarthoff, Roel J Arends, Inge M J Reinieren-Beeren, Marc C B C Paradé, Lilian Driessen-Engels, Karin de Laat-Arts, Désirée Damming, Ellen W H Santegoeds-Lenssen, Daphne W J van Kuppeveld, Imke Lodewijks, Hugo Olsman, Hanke L Matlung, Katka Franke, Ellen Mattaar-Hepp, Marloes E M Stokman, Benny de Wit, Dirk H R F Glaudemans, Daniëlle E J W van Wijk, Lonnie Joosten-Stoffels, Jan Schouten, Paul J Boersema, Monique van der Vleuten, Jorien W H Sanderink, Wendela A Kappers, Diels van den Dobbelsteen, Marco Timmers, Ruud Ubink, Gerard J A Rouwendal, Gijs Verheijden, Miranda M C van der Lee, Wim H A Dokter, Timo K van den Berg

Publikováno v: van Helden, M J, Zwarthoff, S A, Arends, R J, Reinieren-Beeren, I M J, Paradé, M C B C, Driessen-Engels, L, de Laat-Arts, K, Damming, D S, Santegoeds-Lenssen, E W H, van Kuppeveld, D W J, Lodewijks, I, Olsman, H, Matlung, H L, Franke, K, Mattaar-Hepp, E, Stokman, M E M, de Wit, B, Glaudemans, D H R F, van Wijk, D E J W, Joosten-Stoffels, L, Schouten, J, Boersema, P J, van der Vleuten, M, Sanderink, J W H, Kappers, W A, van den Dobbelsteen, D, Timmers, M, Ubink, R, Rouwendal, G J A, Verheijden, G, van der Lee, M M C, Dokter, W H A & van den Berg, T K 2023, ' BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγon T cells ', Journal for Immunotherapy of Cancer, vol. 11, no. 4, jitc-2022-006567 . https://doi.org/10.1136/jitc-2022-006567

BackgroundPreclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies with CD47 blockers. Howeve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f6e6308ed606888d418126a12792c8
https://research.vumc.nl/en/publications/67116c0e-064c-4154-86d3-6797beec296d